Novartis publishes long-term data from SMA gene therapyNovartis has produced data demonstrating its Zolgensma gene therapy produces long term benefits in the rare muscle wasting Share XNovartis publishes long-term data from SMA gene therapyhttps://pharmaphorum.com/news/novartis-publishes-long-term-data-from-sma-gene-therapy/
Roche edges closer to SMA market as risdiplam hits target in trial in babiesRoche is to begin discussions with regulators about new data from risdiplam, its developmental oral treatment for the Share XRoche edges closer to SMA market as risdiplam hits target in trial in babieshttps://pharmaphorum.com/news/roche-sma-risdiplam-babies/
Novartis sets up free lottery for $2.1m SMA drug outside USNovartis is planning to give away 100 doses of its hugely expensive spinal muscular atrophy gene therapy Zolgensma Share XNovartis sets up free lottery for $2.1m SMA drug outside UShttps://pharmaphorum.com/news/novartis-to-give-away/
FDA slaps hold on Zolgensma trials as animal data raises safety questionThe FDA has placed a partial clinical hold on Novartis’ recently-approved gene therapy Zolgensma for spinal muscular atrophy Share XFDA slaps hold on Zolgensma trials as animal data raises safety questionhttps://pharmaphorum.com/news/fda-slaps-hold-on-zolgensma-trials-as-animal-data-raises-safety-question/
Novartis points to Zolgensma long-term benefits amid data scandalNovartis has new data in hand for spinal muscular atrophy (SMA) gene therapy Zolgensma that it hopes will Share XNovartis points to Zolgensma long-term benefits amid data scandalhttps://pharmaphorum.com/news/novartis-points-to-zolgensmas-long-term-benefits-amid-data-scandal/
PTC shares soar after SMA drug data impresses marketAfter failing three times to bring their Duchenne therapy to the US market, PTC Therapeutics might be on Share XPTC shares soar after SMA drug data impresses markethttps://pharmaphorum.com/news/ptc-therapeutics-posts-solid-sma-data/
